These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 16077397

  • 1. Phosphodiesterase type 4 inhibitor rolipram inhibits activation of monocytes during extracorporeal circulation.
    Sato Y, Hiramatsu Y, Homma S, Sato M, Sato S, Endo S, Sohara Y.
    J Thorac Cardiovasc Surg; 2005 Aug; 130(2):346-50. PubMed ID: 16077397
    [Abstract] [Full Text] [Related]

  • 2. Phosphodiesterase type 4 inhibition of activated polymorphonuclear leukocytes in a simulated extracorporeal circulation model.
    Sato Y, Hiramatsu Y, Homma S, Sato S, Onizuka M, Sakakibara Y.
    J Thorac Cardiovasc Surg; 2003 Jan; 125(1):172-7. PubMed ID: 12539001
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Phosphodiesterase type 4 inhibitor prevents acute lung injury induced by cardiopulmonary bypass in a rat model.
    Hamamoto M, Suga M, Nakatani T, Takahashi Y, Sato Y, Inamori S, Yagihara T, Kitamura S.
    Eur J Cardiothorac Surg; 2004 May; 25(5):833-8. PubMed ID: 15082290
    [Abstract] [Full Text] [Related]

  • 5. Phosphodiesterase III inhibition affects platelet-monocyte aggregate formation depending on the axis of stimulation.
    Horn NA, Anastase DM, Hecker KE, Baumert JH, Scheffer GJ, Rossaint R.
    J Cardiothorac Vasc Anesth; 2006 Apr; 20(2):162-6. PubMed ID: 16616654
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. The Type IV phosphodiesterase inhibitor rolipram interferes with drug-induced conditioned place preference but not immediate early gene induction in mice.
    Thompson BE, Sachs BD, Kantak KM, Cherry JA.
    Eur J Neurosci; 2004 May; 19(9):2561-8. PubMed ID: 15128409
    [Abstract] [Full Text] [Related]

  • 8. Inhibition of eotaxin-mediated human eosinophil activation and migration by the selective cyclic nucleotide phosphodiesterase type 4 inhibitor rolipram.
    Santamaria LF, Palacios JM, Beleta J.
    Br J Pharmacol; 1997 Jul; 121(6):1150-4. PubMed ID: 9249251
    [Abstract] [Full Text] [Related]

  • 9. Leukocyte effects of C5a-receptor blockade during simulated extracorporeal circulation.
    Rinder CS, Smith MJ, Rinder HM, Cortright DN, Brodbeck RM, Krause JE, Smith BR.
    Ann Thorac Surg; 2007 Jan; 83(1):146-52. PubMed ID: 17184649
    [Abstract] [Full Text] [Related]

  • 10. Specific type IV phosphodiesterase inhibitor ameliorates cerulein-induced pancreatitis in rats.
    Sato T, Otaka M, Odashima M, Kato S, Jin M, Konishi N, Matsuhashi T, Watanabe S.
    Biochem Biophys Res Commun; 2006 Jul 21; 346(1):339-44. PubMed ID: 16759642
    [Abstract] [Full Text] [Related]

  • 11. Phosphodiesterase 4 inhibitors modulate beta2-adrenoceptor agonist-induced human airway hyperresponsiveness.
    Faisy C, Risse PA, Naline E, Guerot E, Fagon JY, Devillier P, Advenier C.
    Life Sci; 2006 Oct 12; 79(20):1929-35. PubMed ID: 16820175
    [Abstract] [Full Text] [Related]

  • 12. Nafamostat preserves neutrophil deformability and reduces microaggregate formation during simulated extracorporeal circulation.
    Hiramatsu Y, Homma S, Sato Y, Sato S, Matsuzaki K, Shigeta O, Sakakibara Y.
    Ann Thorac Surg; 2005 Apr 12; 79(4):1326-32. PubMed ID: 15797071
    [Abstract] [Full Text] [Related]

  • 13. Rolipram inhibits leukocyte-endothelial cell interactions in vivo through P- and E-selectin downregulation.
    Sanz MJ, Alvarez A, Piqueras L, Cerdá M, Issekutz AC, Lobb RR, Cortijo J, Morcillo EJ.
    Br J Pharmacol; 2002 Apr 12; 135(8):1872-81. PubMed ID: 11959789
    [Abstract] [Full Text] [Related]

  • 14. Antithrombin reduces monocyte and neutrophil CD11b up regulation in addition to blocking platelet activation during extracorporeal circulation.
    Rinder CS, Rinder HM, Smith MJ, Fitch JC, Tracey JB, Chandler WL, Rollins SA, Smith BR.
    Transfusion; 2006 Jul 12; 46(7):1130-7. PubMed ID: 16836559
    [Abstract] [Full Text] [Related]

  • 15. Effect of orally administered rolipram, a phosphodiesterase 4 inhibitor, on a mouse model of the dermatitis caused by 2,4,6-trinitro-1-chlorobenzene (TNCB)-repeated application.
    Harada D, Tsukumo Y, Takashima Y, Manabe H.
    Eur J Pharmacol; 2006 Feb 17; 532(1-2):128-37. PubMed ID: 16442096
    [Abstract] [Full Text] [Related]

  • 16. Effect of rolipram, a phosphodiesterase IV inhibitor, on allergic footpad swelling using various adjuvants in mice.
    Yamaki K, Alam AH, Hossain MA, Taneda S, Yanagisawa R, Takano H, Yoshino S.
    Scand J Immunol; 2005 Oct 17; 62(4):378-84. PubMed ID: 16253125
    [Abstract] [Full Text] [Related]

  • 17. Selective type IV phosphodiesterase inhibitors prevent IL-4-induced IgE production by human peripheral blood mononuclear cells.
    Coqueret O, Boichot E, Lagente V.
    Clin Exp Allergy; 1997 Jul 17; 27(7):816-23. PubMed ID: 9249275
    [Abstract] [Full Text] [Related]

  • 18. Aprotinin inhibits the contact, neutrophil, and platelet activation systems during simulated extracorporeal perfusion.
    Wachtfogel YT, Kucich U, Hack CE, Gluszko P, Niewiarowski S, Colman RW, Edmunds LH.
    J Thorac Cardiovasc Surg; 1993 Jul 17; 106(1):1-9; discussion 9-10. PubMed ID: 7686593
    [Abstract] [Full Text] [Related]

  • 19. Selective inhibition of purified human phosphodiesterase 4A expressed in yeast cell GL62 by ciclamilast, piclamilast, and rolipram.
    Chen JC, Chen JQ, Xie QM, Zhu YL.
    Acta Pharmacol Sin; 2004 Sep 17; 25(9):1171-5. PubMed ID: 15339393
    [Abstract] [Full Text] [Related]

  • 20. Selective inhibition of phosphodiesterase-4 ameliorates chronic colitis and prevents intestinal fibrosis.
    Videla S, Vilaseca J, Medina C, Mourelle M, Guarner F, Salas A, Malagelada JR.
    J Pharmacol Exp Ther; 2006 Feb 17; 316(2):940-5. PubMed ID: 16254133
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.